STING Signaling and Skin Cancers

Recent developments in immunotherapy against malignancies overcome the disadvantages of traditional systemic treatments; however, this immune checkpoint treatment is not perfect and cannot obtain a satisfactory clinical outcome in all cases. Therefore, an additional therapeutic option for malignancy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sayaka Sato, Yu Sawada, Motonobu Nakamura
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	STING skin cancers IFN epigenetics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/213e675a67a3485d89049a4159422752
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:213e675a67a3485d89049a4159422752
record_format	dspace
spelling	oai:doaj.org-article:213e675a67a3485d89049a41594227522021-11-25T17:01:12ZSTING Signaling and Skin Cancers10.3390/cancers132256032072-6694https://doaj.org/article/213e675a67a3485d89049a41594227522021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5603https://doaj.org/toc/2072-6694Recent developments in immunotherapy against malignancies overcome the disadvantages of traditional systemic treatments; however, this immune checkpoint treatment is not perfect and cannot obtain a satisfactory clinical outcome in all cases. Therefore, an additional therapeutic option for malignancy is needed in oncology. Stimulator of interferon genes (STING) has recently been highlighted as a strong type I interferon driver and shows anti-tumor immunity against various malignancies. STING-targeted anti-tumor immunotherapy is expected to enhance the anti-tumor effects and clinical outcomes of immunotherapy against malignancies. In this review, we focus on recent advancements in the knowledge gained from research on STING signaling in skin cancers. In addition to the limitations of STING-targeted immunotherapy, we also discuss the clinical application of STING agonists in the treatment of skin cancer.Sayaka SatoYu SawadaMotonobu NakamuraMDPI AGarticleSTINGskin cancersIFNepigeneticsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5603, p 5603 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	STING skin cancers IFN epigenetics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	STING skin cancers IFN epigenetics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sayaka Sato Yu Sawada Motonobu Nakamura STING Signaling and Skin Cancers
description	Recent developments in immunotherapy against malignancies overcome the disadvantages of traditional systemic treatments; however, this immune checkpoint treatment is not perfect and cannot obtain a satisfactory clinical outcome in all cases. Therefore, an additional therapeutic option for malignancy is needed in oncology. Stimulator of interferon genes (STING) has recently been highlighted as a strong type I interferon driver and shows anti-tumor immunity against various malignancies. STING-targeted anti-tumor immunotherapy is expected to enhance the anti-tumor effects and clinical outcomes of immunotherapy against malignancies. In this review, we focus on recent advancements in the knowledge gained from research on STING signaling in skin cancers. In addition to the limitations of STING-targeted immunotherapy, we also discuss the clinical application of STING agonists in the treatment of skin cancer.
format	article
author	Sayaka Sato Yu Sawada Motonobu Nakamura
author_facet	Sayaka Sato Yu Sawada Motonobu Nakamura
author_sort	Sayaka Sato
title	STING Signaling and Skin Cancers
title_short	STING Signaling and Skin Cancers
title_full	STING Signaling and Skin Cancers
title_fullStr	STING Signaling and Skin Cancers
title_full_unstemmed	STING Signaling and Skin Cancers
title_sort	sting signaling and skin cancers
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/213e675a67a3485d89049a4159422752
work_keys_str_mv	AT sayakasato stingsignalingandskincancers AT yusawada stingsignalingandskincancers AT motonobunakamura stingsignalingandskincancers
_version_	1718412764007890944

STING Signaling and Skin Cancers

Ejemplares similares